Company Atossa Genetics Inc Nasdaq
Equities
US04962H2094
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01/08/01 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01/08/01 |
Heather Rees
DFI | Director of Finance/CFO | - | 01/17/01 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 04/12 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 25/22/25 |
Delly Behen
ADM | Chief Administrative Officer | - | 01/14/01 |
Eric van Zanten
IRC | Investor Relations Contact | - | 07/22/07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01/08/01 |
Director/Board Member | 66 | 01/14/01 | |
H. Remmel
BRD | Director/Board Member | 72 | 01/12/01 |
Shu-Chih Chen
FOU | Founder | 62 | 01/08/01 |
Stephen Galli
BRD | Director/Board Member | 77 | 01/11/01 |
Jonathan Finn
BRD | Director/Board Member | 50 | 08/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 127,077,462 | 125,230,652 ( 98.55 %) | 0 | 98.55 % |
Stock B | 0 | 582 | 0 | 0 |
Company contact information
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+29.77% | 4.95TCr | |
+1.00% | 4.26TCr | |
+50.47% | 4.25TCr | |
-5.26% | 2.91TCr | |
+13.68% | 2.66TCr | |
-22.99% | 1.86TCr | |
+8.22% | 1.32TCr | |
+32.41% | 1.25TCr | |
-1.62% | 1.2TCr |